- Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Quintas-Cardama, A., Kantarjian, H., Jones, D., Nicaise, C., O'brien, S., Giles, F., Talpaz, M., Cortes, J. Blood (2007)